Who ACI is actually for

ACI suits a specific patient profile — and being clear about that profile early saves significant time and uncertainty. NICE Technology Appraisal TA477 (October 2017) sets out the eligibility criteria against which any referral is assessed: a symptomatic, focal, full-thickness cartilage defect of the knee larger than 2 cm², with minimal osteoarthritic change, in a patient who has not previously undergone cartilage repair surgery.

Those four filters — defect size, osteoarthritis grade, prior surgery history, and overall joint condition — do most of the screening work. Patients with diffuse cartilage wear, established OA, or a history of failed marrow-stimulation procedures typically fall outside the optimal profile; NICE's cost-effectiveness modelling rests specifically on the best-prognosis subgroup, assessed as likely under £20,000 per QALY gained.

Age and BMI are further practical considerations. The procedure is most commonly considered for active patients aged under 50 who are trying to preserve their natural joint and delay or avoid joint replacement. A BMI above 30 is associated with higher failure risk and is routinely factored into candidacy discussions.

ACI is not a routine referral pathway. NICE specifies delivery at tertiary referral centres — facilities with the specialist surgical and laboratory infrastructure the procedure demands. For patients in London, this means assessment through a dedicated cartilage service rather than a standard orthopaedic outpatient clinic.

NICE endorsement and what it means in practice

A NICE Technology Appraisal is not simply a committee opinion — it is the output of a structured systematic review of clinical evidence, economic modelling, and stakeholder scrutiny. Receiving a positive appraisal means a treatment has cleared that process and, critically, that NHS commissioners are legally required to fund it within 90 days of publication. For ACI, TA477 arrived in October 2017 after roughly 20 years of clinical trials conducted primarily at the Robert Jones and Agnes Hunt Orthopaedic Hospital in Oswestry — one of the longest pre-endorsement evidence-gathering periods of any orthopaedic technique in the UK. That history matters: it means ACI is not a fringe or experimental intervention but a reimbursed, evidence-reviewed procedure with a defined place in NHS practice.

For patients weighing up private versus NHS access, the NICE endorsement carries a practical implication that is sometimes overlooked. The selection criteria underpinning TA477 are not bureaucratic formalities — they reflect the patient profile for whom the evidence actually demonstrates benefit. Seeking private treatment does not bypass those criteria; it simply changes who funds the assessment and surgery. Applying the same eligibility logic in a private setting is what makes outcomes comparable to the published NHS evidence base. Centres offering ACI outside those parameters are, in effect, operating beyond the evidence that legitimises the procedure.

Long-term outcomes: the honest numbers

The numbers deserve to be stated plainly. A systematic review by Pareek and colleagues (2016), drawing on nine studies and 771 patients with a mean follow-up of 11.4 years and a mean defect size of 5.9 cm², found ACI produced successful outcomes in 82% of cases. The remaining figures — a failure rate of approximately 18% and a reoperation rate of around 37% — are meaningful, and patients weighing up this pathway should understand them before committing. The strongest predictors of a poorer result were older age at implantation and lesion area exceeding 4.5 cm²; both align closely with the candidacy filters covered in earlier sections, and help explain why tight patient selection matters as much as surgical technique.

Twenty-year survivorship data from a JISAKOS 2023 study offer a harder test of durability: 74.4% of patients retained their native knee at two decades (95% CI 60%–91%). For a procedure aimed at younger patients trying to defer joint replacement, that figure makes the joint-preservation argument concrete.

Read together, these results frame ACI honestly — durable for the majority, but not without meaningful risk of further surgery. The reoperation and failure rates are not evenly distributed across all comers; they cluster in cases where age, lesion size, or prior surgical history stretched beyond the best-prognosis profile. That is not a caveat to soften the statistics; it is the mechanism that explains them. Outcome quality at the population level is, in large part, a function of selection quality.

Three generations of ACI: periosteal patch to MACI

The procedure that received NICE endorsement in 2017 was not quite the same one first performed in 1994. Over three decades, ACI has gone through distinct generations — each driven by a specific clinical problem with its predecessor.

First-generation ACI used a strip of periosteal tissue harvested from the shin as a biological flap to cover the injected cell suspension. It worked, but the periosteum had a tendency to overgrow the repair site — a complication known as graft hypertrophy — often requiring a return to theatre to trim the excess tissue. Second-generation ACI addressed this directly by replacing the periosteal harvest with a standardised collagen membrane. The change reduced hypertrophy rates substantially and made the procedure more reproducible across different centres, removing a variable that had made first-generation results harder to generalise.

Third-generation ACI — commercially known as MACI — introduced a more fundamental shift. Rather than injecting a cell suspension at the time of implantation, chondrocytes are pre-seeded onto a porcine collagen scaffold in the laboratory before surgery. The surgeon then cuts the membrane to match the defect and fixes it in place, a technically simpler step that also encourages more uniform cell distribution across the repair area.

The pivotal evidence for MACI came from the SUMMIT randomised controlled trial, published by Brittberg and colleagues in 2018. With more than 500 patients and five-year follow-up, it showed that MACI produced clinically and statistically significant improvements in pain and function compared with microfracture for defects of 3 cm² or larger. For patients choosing between options, that distinction is practical: microfracture — the standard first-line surgical alternative — produces fibrocartilage rather than hyaline-like repair tissue, and its functional gains in larger defects tend to diminish over time. MACI's superiority in the SUMMIT trial, cited by over 330 subsequent studies, is why it is now regarded as the best-evidenced form of ACI for focal defects in this size range.

MACI outcomes at 5, 10, and 17 years

At the longer end of follow-up, MACI's most clinically meaningful figure is TKA conversion: approximately 7.4% of patients go on to total knee arthroplasty over a 10-to-17-year span. That is the clearest published measure of how often MACI delivers on its joint-preservation ambition. Earlier in the outcome curve — at five to ten years — graft survival sits at approximately 78%, and the all-cause reoperation rate is around 9%, a notably lower figure than the 37% reoperation burden documented in first-generation ACI series.

These numbers emerge from different follow-up windows rather than three discrete snapshots: the five-to-ten-year graft survival data captures the period when most failures declare themselves, while TKA conversion rates extend the picture toward two decades, showing that the majority of patients who get through the early phase retain their native knee over the long term.

MACI, as currently practised, remains a two-stage procedure. An arthroscopic biopsy harvests the cartilage sample; several weeks later, after laboratory culture on the collagen membrane, implantation surgery takes place under general anaesthetic. That gap — two separate anaesthetics, a waiting period, and resource-intensive cell processing — carries real logistical weight for patients and providers. It does not diminish MACI's evidence base, but it is the clearest single driver behind the development of single-stage approaches designed to collapse that timetable.

Single-stage and next-generation ACI: where the field is heading

STACi (Scaffold-based Tissue-engineered ACI) collapses the two-stage timetable by keeping the entire procedure within one operative session. A dedicated theatre team enzymatically processes the cartilage biopsy on the day of surgery — releasing chondrocytes without altering their biological character — while bone marrow MSCs are isolated simultaneously. The combined construct is seeded onto a three-dimensional collagen scaffold and implanted within the same 2.5–4 hour session: one anaesthetic, no inter-stage wait, no periosteal harvest. The three-dimensional scaffold supports cell growth in depth as well as across the surface, which may extend eligibility to larger or more complex defects and to joints beyond the knee — including the hip, shoulder, and ankle.

A parallel direction runs toward fully acellular approaches. A 2024 Cartilage Journal review by Debieux and colleagues documents AutoCart™ — minced weight-bearing cartilage combined with autologous fluid matrix in a single session — alongside biofunctionalised hydrogel scaffolds designed to recruit the patient's own progenitor cells without any ex-vivo culture step. The aim across these approaches, as Debieux et al. describe, is to enhance scaffold quality, cell viability, and integration with surrounding tissue: engineering the repair environment rather than relying on transplanted cells.

The evidence position for both directions requires honest framing. Head-to-head randomised trial data comparing STACi or AutoCart directly with MACI do not yet exist; their credibility rests on the established ACI and MACI biological evidence chain — a sound foundation, but not the same as independent trial confirmation. A 2019 paper by Taylor and Lee identified single-treatment ACI as the field's next-generation trajectory and set out the clinical rationale before comparative RCT data became available. Individual suitability across this evolving range of options remains a matter for specialist case-by-case assessment.

For patients considering where they sit in this landscape, an initial consultation is available via londoncartilage.com.

1. [1] Autologous Chondrocyte Implantation – Wikipedia. https://en.wikipedia.org/?curid=19074150 https://en.wikipedia.org/?curid=19074150